GSK pulls Japan Relvar filing for COPD but asthma use on track
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has voluntarily withdrawn a Japanese approval filing for one planned indication of its inhaled combination respiratory therapy Relvar Ellipta, citing internal concerns over the adequacy of supporting clinical data.